TY - JOUR
T1 - The PRSS3P2 and TRY7 deletion copy number variant modifies risk for chronic pancreatitis
AU - the GREPAN (Genetic REsearch on PANcreatitis) Study Group
AU - Masson, Emmanuelle
AU - Ewers, Maren
AU - Paliwal, Sumit
AU - Kume, Kiyoshi
AU - Scotet, Virginie
AU - Cooper, David N.
AU - Rebours, Vinciane
AU - Buscail, Louis
AU - Rouault, Karen
AU - Abrantes, Amandine
AU - Aguilera Munoz, Lina
AU - Albouys, Jérémie
AU - Alric, Laurent
AU - Amiot, Xavier
AU - Archambeaud, Isabelle
AU - Audiau, Solène
AU - Bastide, Laetitia
AU - Baudon, Julien
AU - Bellaiche, Guy
AU - Bellon, Serge
AU - Bertrand, Valérie
AU - Bideau, Karine
AU - Billiemaz, Kareen
AU - Billioud, Claire
AU - Bonnefoy, Sabine
AU - Borderon, Corinne
AU - Bournet, Barbara
AU - Breton, Estelle
AU - Brugel, Mathias
AU - Cadiot, Guillaume
AU - Camus, Marine
AU - Carpentier-Pourquier, Marine
AU - Chamouard, Patrick
AU - Chaput, Ulriikka
AU - Chen, Jian Min
AU - Cholet, Franck
AU - Ciocan, Dragos Marius
AU - Clavel, Christine
AU - Coffin, Benoit
AU - Coimet-Berger, Laura
AU - Cosconea, Simona
AU - Creveaux, Isabelle
AU - Culetto, Adrian
AU - Daboussi, Oussama
AU - De Mestier, Louis
AU - Degand, Thibault
AU - D'engremont, Christelle
AU - Denis, Bernard
AU - Dermine, Solène
AU - Witt, Heiko
N1 - Publisher Copyright:
© 2022 IAP and EPC
PY - 2023/1
Y1 - 2023/1
N2 - Background: PRSS1 and PRSS2 constitute the only functional copies of a tandemly-arranged five-trypsinogen-gene cluster (i.e., PRSS1, PRSS3P1, PRSS3P2, TRY7 and PRSS2) on chromosome 7q35. Variants in PRSS1 and PRSS2, including missense and copy number variants (CNVs), have been reported to predispose to or protect against chronic pancreatitis (CP). We wondered whether a common trypsinogen pseudogene deletion CNV (that removes two of the three trypsinogen pseudogenes, PRSS3P2 and TRY7) might be associated with CP causation/predisposition. Methods: We analyzed the common PRSS3P2 and TRY7 deletion CNV in a total of 1536 CP patients and 3506 controls from France, Germany, India and Japan by means of quantitative fluorescent multiplex polymerase chain reaction. Results: We demonstrated that the deletion CNV variant was associated with a protective effect against CP in the French, German and Japanese cohorts whilst a trend toward the same association was noted in the Indian cohort. Meta-analysis under a dominant model yielded a pooled odds ratio (OR) of 0.68 (95% confidence interval (CI) 0.52–0.89; p = 0.005) whereas an allele-based meta-analysis yielded a pooled OR of 0.84 (95% CI 0.77–0.92; p = 0.0001). This protective effect is explicable by reference to the recent finding that the still functional PRSS3P2/TRY7 pseudogene enhancers upregulate pancreatic PRSS2 expression. Conclusions: The common PRSS3P2 and TRY7 deletion CNV was associated with a reduced risk for CP. This finding provides additional support for the emerging view that dysregulated PRSS2 expression represents a discrete mechanism underlying CP predisposition or protection.
AB - Background: PRSS1 and PRSS2 constitute the only functional copies of a tandemly-arranged five-trypsinogen-gene cluster (i.e., PRSS1, PRSS3P1, PRSS3P2, TRY7 and PRSS2) on chromosome 7q35. Variants in PRSS1 and PRSS2, including missense and copy number variants (CNVs), have been reported to predispose to or protect against chronic pancreatitis (CP). We wondered whether a common trypsinogen pseudogene deletion CNV (that removes two of the three trypsinogen pseudogenes, PRSS3P2 and TRY7) might be associated with CP causation/predisposition. Methods: We analyzed the common PRSS3P2 and TRY7 deletion CNV in a total of 1536 CP patients and 3506 controls from France, Germany, India and Japan by means of quantitative fluorescent multiplex polymerase chain reaction. Results: We demonstrated that the deletion CNV variant was associated with a protective effect against CP in the French, German and Japanese cohorts whilst a trend toward the same association was noted in the Indian cohort. Meta-analysis under a dominant model yielded a pooled odds ratio (OR) of 0.68 (95% confidence interval (CI) 0.52–0.89; p = 0.005) whereas an allele-based meta-analysis yielded a pooled OR of 0.84 (95% CI 0.77–0.92; p = 0.0001). This protective effect is explicable by reference to the recent finding that the still functional PRSS3P2/TRY7 pseudogene enhancers upregulate pancreatic PRSS2 expression. Conclusions: The common PRSS3P2 and TRY7 deletion CNV was associated with a reduced risk for CP. This finding provides additional support for the emerging view that dysregulated PRSS2 expression represents a discrete mechanism underlying CP predisposition or protection.
KW - Case-control study
KW - Causal variant
KW - Genetic predisposition to disease
KW - Pancreatic tissue
KW - rs10273639
UR - http://www.scopus.com/inward/record.url?scp=85145973987&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2022.11.013
DO - 10.1016/j.pan.2022.11.013
M3 - Article
C2 - 36517351
AN - SCOPUS:85145973987
SN - 1424-3903
VL - 23
SP - 48
EP - 56
JO - Pancreatology
JF - Pancreatology
IS - 1
ER -